よむ、つかう、まなぶ。
資料4-3 クロミフェンクエン酸塩 (23 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00022.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第50回 1／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
5） 仏国添付文書：CLOMID 50 mg, comprimé（Sanofi）
6） 豪州添付文書：Clomid（Sanofi）
7） Quigley MM, et al. Enhanced follicular recruitment in an in vitro fertilization program:
clomiphene alone versus a clomiphene/human menopausal gonadotropin combination. Fertil
Steril 1984; 42: 25-33.
8） Kingsland C, et al. The routine use of gonadotropin-releasing hormone agonists for all patients
undergoing in vitro fertilization. Is there any medical advantage? A prospective randomized
study. Fertil Steril 1992; 57: 804-9.
9） Tummon IS, et al. Randomized, prospective comparison of luteal leuprolide acetate and
gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro
fertilization. Fertil Steril 1992; 58: 563-8.
10）Harrison RF, et al. Should gonadotropin-releasing hormone down-regulation therapy be routine
in in vitro fertilization? Fertil Steril 1994; 62: 568-73.
11）MacDougall MJ, et al. Comparison of natural with clomiphene citrate-stimulated cycles in in
vitro fertilization: a prospective, randomized trial. Fertil Steril 1994; 61: 1052-7.
12）Long CA, et al. Luteal phase consequences of low-dose gonadotropin-releasing hormone agonist
therapy in nonluteal-supported in vitro fertilization cycles. Fertil Steril 1995; 64: 573-6.
13 ） Grochowski D, et al. Good results of milder form of ovarian stimulation in an in vitro
fertilization/intracytoplasmic sperm injection program. Gynecol Endocrinol 1999; 13: 297-304.
14）Ingerslev HJ, et al. A randomized study comparing IVF in the unstimulatedcycle with IVF
following clomiphene citrate. Hum Reprod 2001; 16: 696–702.
15）Weigert M, et al. Comparison of stimulation with clomiphene citrate in combination with
recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation
with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study. Fertil
Steril 2002; 78: 34-9.
16 ） Lin YH, et al. Comparison of outcome of clomiphene citrate/human menopausal
gonadotropin/cetrorelix protocol and buserelin long protocol - a randomized study.
Gynecological Endocrinology 2006; 22: 297-302.
17）Karimzadeh MA, et al. Comparison of mild stimulation and conventional stimulation in ART
outcome. Arch Gynecol Obstet 2010; 281: 741–6.
18）Karimzadeh MA, et al. Comparison of mild and microdose GnRH agonist flare protocolson IVF
outcome in poor responders. Arch Gynecol Obstet 2011; 283: 1159–64.
19）Revelli A, et al. "Mild" vs. "long" protocol for controlled ovarian hyperstimulation in patients
with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large
prospective randomized trial. J Assist Reprod Genet. 2014; 31: 809-15.
20）Pilehvari S, et al. Comparison Pregnancy Outcomes Between Minimal Stimulation Protocol and
Conventional GnRH Antagonist Protocols in Poor Ovarian Responders. J Family Reprod Health.
23
6） 豪州添付文書：Clomid（Sanofi）
7） Quigley MM, et al. Enhanced follicular recruitment in an in vitro fertilization program:
clomiphene alone versus a clomiphene/human menopausal gonadotropin combination. Fertil
Steril 1984; 42: 25-33.
8） Kingsland C, et al. The routine use of gonadotropin-releasing hormone agonists for all patients
undergoing in vitro fertilization. Is there any medical advantage? A prospective randomized
study. Fertil Steril 1992; 57: 804-9.
9） Tummon IS, et al. Randomized, prospective comparison of luteal leuprolide acetate and
gonadotropins versus clomiphene citrate and gonadotropins in 408 first cycles of in vitro
fertilization. Fertil Steril 1992; 58: 563-8.
10）Harrison RF, et al. Should gonadotropin-releasing hormone down-regulation therapy be routine
in in vitro fertilization? Fertil Steril 1994; 62: 568-73.
11）MacDougall MJ, et al. Comparison of natural with clomiphene citrate-stimulated cycles in in
vitro fertilization: a prospective, randomized trial. Fertil Steril 1994; 61: 1052-7.
12）Long CA, et al. Luteal phase consequences of low-dose gonadotropin-releasing hormone agonist
therapy in nonluteal-supported in vitro fertilization cycles. Fertil Steril 1995; 64: 573-6.
13 ） Grochowski D, et al. Good results of milder form of ovarian stimulation in an in vitro
fertilization/intracytoplasmic sperm injection program. Gynecol Endocrinol 1999; 13: 297-304.
14）Ingerslev HJ, et al. A randomized study comparing IVF in the unstimulatedcycle with IVF
following clomiphene citrate. Hum Reprod 2001; 16: 696–702.
15）Weigert M, et al. Comparison of stimulation with clomiphene citrate in combination with
recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation
with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study. Fertil
Steril 2002; 78: 34-9.
16 ） Lin YH, et al. Comparison of outcome of clomiphene citrate/human menopausal
gonadotropin/cetrorelix protocol and buserelin long protocol - a randomized study.
Gynecological Endocrinology 2006; 22: 297-302.
17）Karimzadeh MA, et al. Comparison of mild stimulation and conventional stimulation in ART
outcome. Arch Gynecol Obstet 2010; 281: 741–6.
18）Karimzadeh MA, et al. Comparison of mild and microdose GnRH agonist flare protocolson IVF
outcome in poor responders. Arch Gynecol Obstet 2011; 283: 1159–64.
19）Revelli A, et al. "Mild" vs. "long" protocol for controlled ovarian hyperstimulation in patients
with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large
prospective randomized trial. J Assist Reprod Genet. 2014; 31: 809-15.
20）Pilehvari S, et al. Comparison Pregnancy Outcomes Between Minimal Stimulation Protocol and
Conventional GnRH Antagonist Protocols in Poor Ovarian Responders. J Family Reprod Health.
23